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ABSTRACT 30 
 31 
The chimeric fusion oncogene EBF1-PDGFRB is a recurrent lesion observed in Ph-like 32 
B-ALL and is associated with particularly poor prognosis. While it is understood that this 33 
fusion activates tyrosine kinase signaling, the mechanisms of transformation and 34 
importance of perturbation of EBF1 activity remain unknown. EBF1 is a nuclear 35 
transcription factor required for normal B-lineage specification, commitment, and 36 
development. Conversely, PDGFRB is a receptor tyrosine kinase that is normally 37 
repressed in lymphocytes, yet PDGFRB remains a common fusion partner in leukemias. 38 
Here, we demonstrate that the EBF1-PDGFRB fusion results in loss of EBF1 function, 39 
multimerization and autophosphorylation of the fusion protein, activation of STAT5 40 
signaling, and gain of IL-7-independent cell proliferation. Deregulation and loss of EBF1 41 
function is critically dependent on the nuclear export activity of the TM domain of 42 
PDGFRB. Deletion of the TM domain partially rescues EBF1 function and restores IL-7 43 
dependence, without requiring kinase inhibition. Moreover, we demonstrate that EBF1-44 
PDGFRB synergizes with loss of IKAROS function in a fully penetrant B-ALL in vivo. 45 
Thus, we establish that EBF1-PDGFRB is sufficient to drive leukemogenesis through 46 
TM-dependent loss of transcription factor function, increased proliferation and synergy 47 
with additional genetic insults including loss of IKAROS function.  48 
49 
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INTRODUCTION 50 
 51 
Notwithstanding a 5-year event-free survival rate surpassing 90%, acute lymphoblastic 52 
leukemia (ALL) remains a leading cause of cancer-related death for individuals under 53 
40.1 Hallmarks of leukemic cells include the inability to differentiate into mature 54 
lymphocytes and unregulated cellular proliferation.2 Ph-like (Philadelphia-like; BCR-55 
ABL1-like) ALL is a high-risk subtype of B cell precursor ALL defined by a gene 56 
expression profile similar to Ph+ ALL.3 Characteristically, Ph-like ALL has a diverse 57 
range of chromosomal rearrangements, mutations, and DNA copy number alterations 58 
that deregulate cytokine receptor and tyrosine kinase (TK) signaling.(4 Chromosomal 59 
rearrangements in Ph-like ALL commonly result in fusions between lymphoid 60 
transcription factor and TK genes. One such fusion, early B cell factor 1–platelet derived 61 
growth factor receptor beta (EBF1-PDGFRB), arises from reciprocal translocation or 62 
interstitial deletion events between EBF1 exon 15 to PDGFRB exon 11 located at 5q33 63 
(Figure 1a).3, 5 EBF1 is the most common fusion partner with PDGFRB observed in Ph-64 
like ALL. Like other PDGFRB fusions, it retains both the transmembrane (TM) and 65 
tyrosine kinase (TK) domains (Supplementary Figure 1).6-8 EBF1-PDGFRB occurs in 66 
∼8% of Ph-like patients, is enriched in ~30% patients with other B-ALL subtypes who 67 
experience induction failure, and is associated with higher relapse rates.5,9 Patients 68 
harboring the EBF1-PDGFRB fusion frequently have additional genomic lesions 69 
resulting in the loss or competitive inhibition of essential B lymphoid transcription factor 70 
genes including IKZF1 (IKAROS), loss of the non-rearranged allele of EBF1 and/or 71 
PAX5, and deletion of CDKN2A/B (encoding the cell cycle regulators and tumor 72 
suppressors ARF and INK4A/B). EBF1-PDGFRB results in cytokine-independent 73 
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proliferation of non-ALL cell lines and human EBF1-PDGFRB leukemic cells are 74 
sensitive to tyrosine kinase inhibitors (TKI).3 75 
The transcription factor EBF1 is essential for normal B lymphocyte specification, 76 
commitment and differentiation.10-13 Loss of EBF1 results in developmental arrest at the 77 
common lymphoid progenitor (CLP) stage.13, 14 In mice, Ebf1 haploinsufficiency results 78 
in inappropriate expression of non-B lineage genes and leukemogenesis when paired 79 
with constitutively active Stat5.15-17 Changes in EBF1-dependent transcription have 80 
been documented in human ALL blast cells harboring mono- or bi-allelic EBF1 81 
deletions.18 Additionally, EBF1 is mutated or deleted in ∼8% of primary B-ALL patients 82 
and ∼25% of relapsed patients, suggesting it functions as a tumor suppressor.18, 19  83 
While it is known that chimeric fusion proteins often drive constitutive kinase 84 
signaling in leukemic cells, few data exist revealing how these proteins perturb lymphoid 85 
development and contribute to oncogenesis. Mechanistically, it is unclear whether 86 
rearrangement of PDGFRB to EBF1 is necessary for PDGFRB activation, or whether 87 
the fusion results in loss of EBF1 function. Moreover, it unknown whether EBF1-88 
PDGFRB promotes oncogenesis by other mechanisms in addition to its unregulated TK 89 
activity, or how multiple lesions cooperate with EBF1-PDGFRB to promote 90 
leukemogenesis in Ph-like B-ALL.3 91 
Here, we report that EBF1-PDGFRB drives leukemogenesis through TM-92 
dependent cytoplasmic mislocalization, which prevents EBF1 from activating 93 
transcription. Additionally, we use the first genetically faithful Ph-like B-ALL mouse 94 
model to quantify the synergism between EBF1-PDGFRB and dominant negative 95 
IKAROS (IK6), which promote leukemogenesis in combination with Arf deletion in vivo.96 
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MATERIALS AND METHODS 97 
Identification of human PDGFRB fusion genes, cloning, and transduction  98 
PDGFRB fusions were identified from RNA-sequencing and RT-PCR of ALL cohorts 99 
with Ph-like ALL, with the exception of TNIP1ex17-PDGFRB, which was identified from 100 
RNA-seq of AML cases as previously described.3, 20 All PDGFRB fusions were amplified 101 
from leukemic cell cDNA, cloned into Zero Blunt TOPO vector (Thermo Scientific, IL, 102 
USA), and then subcloned into the MSCV-IRES-GFP (MIG) or MSCV-IRES-mCFP 103 
(expressing mCherry Fluorescent Protein) retroviral vectors.  Retroviral supernatants 104 
produced using 293T or Phoenix packaging cell lines were used to infect murine Ebf1–/– 105 
fetal liver progenitors, Ba/F3 and primary Arf–/– pre-B cells as described.21 Cell culture 106 
conditions and generation of epitope- and GFP-tagged deletion/mutation constructs are 107 
detailed in Supplementary Methods.  108 
 109 
Quantitative RT-PCR 110 
Isolation of RNA and RT-PCR analysis from retrovirus-infected cells was described 111 
previously.15 Primers are listed in Supplementary Table 1.  112 
 113 
Fluorescence microscopy 114 
Detailed methods for the infection and sorting of Ebf1–/– cells, plasmacytomas, and 115 
Ba/F3 cells, and analysis using confocal fluorescence microscopy are provided in the 116 
Supplementary Methods.  117 
 118 
Immunoblotting and co-immunoprecipitation  119 
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Preparation of whole cell extracts and co-IP of proteins are available in Supplementary 120 
Methods.  121 
 122 
Clonogenic assays, FACS/immunophenotyping and phosphoflow  123 
All mice experiments were reviewed and approved by the St. Jude Children’s Research 124 
Hospital Institutional Animal Care and Use Committee. Culture conditions, staining, and 125 
analysis of cells are described in Supplementary Methods. 126 
 127 
In vivo leukemogenesis 128 
Generation of retrovirally transduced cells, injection into mice, and subsequent analysis 129 
are described in detail in Supplementary Methods.  130 
 131 
In vitro drug sensitivity assays 132 
Tyrosine kinase inhibitor (TKI) sensitivity was assessed using the CellTiter-Blue Cell 133 
Viability Assay (Promega, WI, USA) as per manufacturer’s instructions. IC50 was 134 
determined using nonlinear regression (GraphPad Prism, CA, USA). Each experiment 135 
was performed three times. 136 
 137 
Statistical analyses 138 
Data analyses were performed using GraphPad Prism Version 6.0 (GraphPad, CA, 139 
USA). For qRT-PCR, P values were obtained using a 2-way ANOVA comparing column 140 
means of log transformed values (Y=Log(Y)) with Tukey’s correction for multiple 141 
comparisons. For Ebf1–/– cell counts (Figure 4a; Supplementary Figures 9, 11) a 2-way 142 
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repeated measures ANOVA using Tukey’s correction for multiple comparisons was 143 
used to compare means across continuous time points. All P values are described in 144 
figures. All data are presented as mean ± SD. For Kaplan Meier curves significance was 145 
determined using ANOVA test or Mantle-Cox log rank. P values less than 0.05 were 146 
considered significant. 147 
 148 
RESULTS 149 
 150 
The fusion oncoprotein EBF1-PDGFRB lacks EBF1 function 151 
To determine whether EBF1-PDGFRB can activate EBF1 gene targets we generated 152 
FLAG-tagged versions of human EBF1, PDGFRB, EBF1-PDGFRB, or kinase-inactive 153 
mutant EBF1-PDGFRB(K634R)22, each with an IRES-driven GFP marker for FACS 154 
purification (Figure 1, Supplementary Figures 2 and 3). Because it was recently 155 
reported that removal of the TM domain from a related fusion (TEL-PDGFRB) reduced 156 
its ability to impart IL-3 independence to Ba/F3 cells,23 we also tested EBF1-157 
PDGFRB(∆TM) lacking the 24-residue TM domain, and EBF1-TM, which fuses the TM 158 
domain (plus 22 surrounding juxtamembrane residues) to EBF1 residues 1-583 159 
(Supplementary Figures 2 and 3).  160 
Using retroviruses, we expressed EBF1 and EBF1-PDGFRB proteins in mouse 161 
fetal-liver-derived Ebf1–/– B-progenitor cells cultured with stem cell factor (SCF), Fms-162 
related tyrosine kinase 3 ligand (FLT3L), and interleukin-7 (IL-7).24 On day 3 post-163 
infection we purified GFP+ cells and quantitated expression of archetypal EBF1 target 164 
genes using qRT-PCR. As expected, wild type EBF1 activated transcription of all B cell-165 
specific genes robustly (by as much as 1000-fold for Igll1 and Vpreb1) relative to “empty” 166 
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MIG (Figure 1b; P<0.0001). EBF1-mediated gene activation was unaffected by addition 167 
of the TKI imatinib mesylate (Gleevec, STI-571). Unlike EBF1, EBF1-PDGFRB failed to 168 
activate five of the six target genes significantly. Igll1 was activated weakly (2-3-fold), 169 
but significantly (P<0.03). Similarly weak activation of Pax5 by EBF1-PDGFRB was 170 
observed, but significance was only achieved in the presence of imatinib. Kinase-171 
inactive mutant EBF1-PDGFRB(K634R) produced significant (P=0.002, and P<0.0001), 172 
albeit modest (2-3-fold), activation of Igll1 and Cd79b, respectively, but in considerably 173 
smaller amounts relative to the large increases generated by wild type EBF1.  174 
As deletion of the TM domain resulted in re-localization of the fusion protein to 175 
nuclei, we examined the consequences of this phenomenon on transcriptional activation 176 
of EBF1 targets. Surprisingly, EBF1-PDGFRB(∆TM) significantly activated five of the six 177 
EBF1 target genes examined (Figure 1b; P<0.0001, compared with MIG), while also 178 
repressing non-B lineage genes, such as CD244 (Supplementary Figure 4). Moreover, 179 
EBF1-PDGFRB(∆TM) significantly activated EBF1 targets when compared with EBF1-180 
PDGFRB or EBF1-PDGFRB(K634R). Interestingly, Asb2 was the only EBF1 target not 181 
activated significantly by EBF1-PDGFRB(∆TM); however, it was activated ~2-3-fold by 182 
EBF1-PDGFRB(K634R) relative to EBF1-PDGFRB (P<0.001) or EBF1-PDGFRB(∆TM). 183 
The lack of activation by EBF1-PDGFRB(∆TM) is likely due to the dependence of Asb2 184 
transcription on the C-terminal activation domain of EBF1, which may be functionally 185 
impaired by its fusion to the TK domain of PDGFRB.25 Thus, the oncoprotein EBF1-186 
PDGFRB lacks normal EBF1 function, which can be rescued to a far greater degree by 187 
TM deletion than by inhibition of kinase activity using imatinib or inactivation of the 188 
kinase domain by mutation. Contrary to TM-deletion, fusion of the TM domain to EBF1 189 
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(EBF1-TM) reduced the ability of EBF1 ability to activate five of the gene targets 190 
examined (Pax5 is an exception, but overall activation of this gene is weak compared 191 
with other genes) when compared to wild type EBF1. 192 
  193 
The TM domain drives subcellular mislocalization of EBF1-PDGFRB   194 
To determine whether loss of EBF1 function is due to its subcellular mislocalization, we 195 
fused EBF1 and EBF1-PDGFRB to enhanced GFP (Supplementary Figures 2 and 3b), 196 
which did not alter function (Supplementary Figures 5a-b, 5d). We then imaged live 197 
Ebf1–/– cells co-infected to express GFP-tagged proteins as well as untethered mCFP, 198 
which served as an internal control. When untethered, GFP and mCFP each localized 199 
diffusely throughout both nuclei and cytoplasm (Figure 2a). As expected, EBF1-GFP 200 
localized solely within nuclei (Figure 2b). Surprisingly, wild type PDGFRB-GFP localized 201 
into cytoplasmic aggregates (Figure 2c) and was not detected on the surface of Ebf1–/– 202 
cells by flow cytometry (Supplementary Figure 5c). As a control, retrovirally expressed 203 
PDGFRB-GFP was displayed on the surface of plasmacytoma cells (Supplementary 204 
Figure 5b,d); therefore, the inability of Ebf1–/– progenitors to display this receptor on the 205 
cell surface is similar to normal pre-pro-B cells, which do not display surface PDGFRB 206 
(S.J.W., data not shown). We conclude that normal pre-pro-B cells and Ebf1–/– 207 
progenitors may lack a protein(s) necessary for display of surface PDGFRB. 208 
 Unlike EBF1 and PDGFRB, EBF1-PDGFRB localized diffusely throughout the 209 
cytoplasm and was virtually undetectable in nuclei (Figure 2d). Cytoplasmic localization 210 
using direct immunostaining was also observed in Ba/F3 cells expressing EBF1-211 
PDGFRB and other PDGFRB fusions (Supplementary Figure 6a). Ba/F3 subcellular 212 
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fractionation revealed that PDGFRB fusion proteins were detected only in the total 213 
membrane-bound fraction and not in the nuclear or free cytosolic compartments 214 
(Supplementary Figure 6b). This cytoplasmic and membrane-associated localization 215 
explains the greatly reduced ability of EBF1-PDGFRB to activate EBF1 gene targets. 216 
Importantly, inactivation of the kinase domain by imatinib or (K634R)-mutation failed to 217 
relocate EBF1-PDGFRB into nuclei (Figure 2e, Supplementary Figures 7d-e).  218 
Examination of the TM domain sequence using the prediction server NetNES1.1 219 
suggested a role as a nuclear export signal peptide (NES).26 In support of this, we 220 
discovered that removing the TM domain completely re-localized EBF1-PDGFRB from 221 
the cytoplasm into nuclei (Figures 2f-g; Supplementary Figures 7f-g) where it activated 222 
(Figure 1b) or repressed (Supplementary Figure 4) EBF1 targets regardless of TK 223 
activity. We confirmed the NES activity of the TM domain by appending it to EBF1 224 
(EBF1-TM) (Figure 2h), and also to GFP alone (TM:GFP; Supplementary Figures 2, 3b 225 
and 6c). EBF1-TM localized into cytoplasmic puncti and failed to activate most EBF1 226 
target genes (Figures 1b and 2h, Supplementary Figure 4a).  227 
To determine whether EBF1 is necessary for the cytoplasmic localization of 228 
EBF1-PDGFRB, we generated PDGFRB(528-1106) consisting of only PDGFRB-derived 229 
fusion protein sequences (Supplementary Figures 2 and 3b). Similar to full-length WT 230 
PDGFRB, PDGFRB(528-1106) formed cytoplasmic puncti (Supplementary Figure 8b), 231 
which were also observed using imatinib-treated PDGFRB(528-1106) (data not shown) 232 
or PDGFRB(528-1106)(K634R) (Supplementary Figure 8c). Unlike EBF1-233 
PDGFRB(∆TM), PDGFRB(528-1106)(∆TM) and PDGFRB(528-1106)(∆TM K634R) 234 
Running head: EBF1-PDGFRB IN B-CELL LEUKEMOGENESIS  
 
 11
fragments did not relocate into nuclei, but localized diffusely (Supplementary Figures 235 
8d-e). 236 
 237 
EBF1-PDGFRB homodimerizes, is autophosphorylated, and is stable relative to 238 
PDGFRB 239 
Normal PDGFRB signaling requires ligand-induced dimerization at the plasma 240 
membrane.27 To determine whether EBF1-PDGFRB multimerizes we performed co-IP 241 
followed by immunoblotting of Ebf1–/– progenitors co-transduced with FLAG- and MYC-242 
tagged EBF1-PDGFRB. Pull down of FLAG-tagged EBF1-PDGFRB co-243 
immunoprecipitated MYC-tagged EBF1-PDGFRB, and vice versa, confirming EBF1-244 
PDGFRB multimerization (Figure 3a). Additionally, HA-tagged TNIP1ex14-PDGFRB co-245 
immunoprecipitated His6-tagged TNIP1ex14-PDGFRB (Supplementary Figure 6d) 246 
establishing that cytoplasmic self-association is common among PDGFRB fusion 247 
proteins. Importantly, confocal imaging revealed that co-expression of GFP-tagged 248 
EBF1-PDGFRB together with mCFP-tagged EBF1 did not alter the cytoplasmic or 249 
nuclear localization of either protein, respectively, in B cell progenitors (Figure 3b). This 250 
suggests that unlike sequestration of wild type IKAROS to the cytoplasm by IK6, EBF1 251 
and EBF1-PDGFRB are sequestered to different subcellular compartments. This in turn 252 
effectively prevents the assembly of heterodimers (EBF1 + EBF1-PDGFRB) in cells. It 253 
also explains our inability to detect heterodimers using co-IP (data not shown). Thus, 254 
loss of EBF1 function results from its fusion to PDGFRB and not to dominant negative 255 
effects of EBF1-PDGFRB on EBF1.  256 
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 Next, we determined whether EBF1-PDGFRB is capable of autophosphorylation. 257 
After transducing Ebf1–/– cells with FLAG-tagged versions of EBF1-PDGFRB or EBF1-258 
PDGFRB(K634R) we performed IP followed by immunoblotting with pan-259 
phosphotyrosine (pTyr) antibodies. EBF1-PDGFRB was strongly phosphorylated, which 260 
was inhibited by imatinib or the EBF1-PDGFRB(K634R) mutation (Figure 3c).  261 
 Typically, PDGFRB is internalized and degraded upon ligand-induced 262 
dimerization.22, 28, 29 Given PDGFRB’s lack of surface expression on Ebf1–/– cells and 263 
punctal localization compared with the diffuse cytoplasmic pattern of EBF1-PDGFRB 264 
(Figures 2c-d and Supplementary Figure 5c), we wanted to determine whether 265 
PDGFRB was less stable than EBF1-PDBFRB. We incubated Ebf1–/– cells expressing 266 
these proteins with the translation inhibitor cycloheximide for 0, 4, 8 or 12 hours prior to 267 
immunoblotting (Figure 3d). As expected, PDGFRB levels were greatly reduced after 268 
only 4 hours, whereas EBF1-PDGFRB, EBF1-PDGFRB(K634R) and EBF1-269 
PDGFRB(∆TM) levels were unchanged up to 8 hours and decreased only slightly at 12 270 
hours. Additionally, removal of EBF1 greatly reduced the stability of the PDGFRB(528-271 
1106) fragment.  272 
 273 
EBF1-PDGFRB promotes cytokine-independent and clonogenic growth of B cell 274 
progenitors, which is targetable by TKI therapy 275 
To determine whether EBF1-PDGFRB is sufficient to transform IL-7-dependent Ebf1–/– 276 
progenitors, we transduced these cells with various constructs and expanded infected 277 
cells over 16 days with SCF and FLT3L, but without IL-7. As expected, only EBF1-278 
PDGFRB-positive cells proliferated (Figure 4a).3 Removal of SCF and/or FLT3L 279 
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revealed significant contributions of these cytokines to the growth rates of EBF1-280 
PDGFRB-positive cells (Supplementary Figure 9). Unexpectedly, both EBF1-281 
PDGFRB(∆TM) and PDGFRB(528-1106)-positive cells failed to proliferate in the 282 
absence of IL-7 at any time despite having a functional PDGFRB kinase domain (Figure 283 
4a). Our results establish that, along with a functioning TK domain, fusion of EBF1 to 284 
PDGFRB(528-1106) and TM-mediated cytoplasmic localization of EBF1-PDGFRB are 285 
also necessary to achieve EBF1-PDGFRB-mediated cytokine independence.  286 
We then confirmed that exogenous cytokines are not required for proliferation of 287 
IL3-dependent Ba/F3 pro-B cells or IL7-dependent primary mouse Arf–/– pre-B cells 288 
expressing PDGFRB fusions to EBF1, TNIP1, ATF7IP, or CD74 (Figure 4a-b). In 289 
patients harboring rearrangements of PDGFRB, these lesions frequently co-occur with 290 
IKZF1 alterations and CDKN2A (Arf–/–) deletions; therefore, we co-expressed the 291 
dominant negative IKZF1 isoform (IK6) with each of the fusions in Arf–/– pre-B cells, 292 
which provide a genetically faithful model of human B-ALL. Co-expression of IK6 did not 293 
significantly increase the proliferation rates of ATF7IP-PDGFRB or EBF1-PDGFRB-294 
expressing pre-B cells. However, IK6 co-expression was required for the growth of 295 
TNIP1ex14-PDGFRB-positive pre-B cells; Arf–/– cells expressing TNIP1ex14-PDGFRB 296 
without IK6 do not survive in the absence of IL-7, and therefore, were not included in the 297 
growth assay (Figure 4b). 298 
Mechanistically, PDGFRB fusions to EBF1, TNIP1, or ATF7IP activate the 299 
STAT5 pathway to bypass the cytokine dependence in both Ba/F3 and Arf–/– cells 300 
(Figure 4c).3, 8 This activation can be reversed by treatment with the TKI dasatinib. 301 
Likewise, in Ebf1–/– cells lacking IL-7, EBF1-PDGFRB expression activated STAT5 302 
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signaling, which was blocked by imatinib or mutant EBF1-PDGFRB(K634R) kinase 303 
inhibition (Supplementary Figure 10). Surprisingly, cells expressing EBF1-304 
PDGFRB(∆TM), which failed to expand in the absence of IL-7, still activated STAT5 but 305 
to a lesser extent than full-length EBF1-PDGFRB (Figure 4a, Supplementary Figure 10). 306 
Next, we performed cytotoxicity assays in vitro to assess the relative sensitivities of 307 
fusion proteins to the commonly used TKI dasatinib, but also to the class III TK 308 
inhibitors crenolanib and dovitinib.30-32 Crenolanib binds the active confirmation of 309 
PDGFRA and has been utilized for treatment of imatinib-resistant gastrointestinal 310 
stromal tumors, as has the multi-kinase-inhibitor dovitinib. (Figure 4d). Each of the three 311 
TKI’s potently inhibited proliferation of cells expressing the PDGFRB fusion proteins.  312 
We then expressed EBF1-PDGFRB, TNIP1ex14-PDGFRB, and empty vector in 313 
C57Bl/6 WT and Arf–/– lineage-negative bone marrow hematopoietic progenitors and 314 
assessed colony-forming potential over serial re-platings in vitro as a surrogate 315 
measure of self-renewal. All fusions failed at serial re-plating under myeloid conditions 316 
(IL3, IL6, SCF, GM-CSF; data not shown), but induced serial re-plating under lymphoid 317 
conditions (IL7, SCF, FLT3L; Figure 5a). Morphological (Figure 5b) and flow-cytometric 318 
(Figure 5c) analyses of colony-forming cells harvested after rounds 3-6 of re-plating 319 
revealed a lymphoid phenotype. TNIP1ex14-PDGFRB expression required concomitant 320 
loss of Arf in order to promote serial re-plating for B-progenitor lymphoid colonies. In 321 
contrast, EBF1-PDGFRB potently supported serial B-progenitor colony re-plating in a 322 
WT background with enhanced re-plating in Arf-null cells, supporting the notion that 323 
concomitant activation of kinase signaling and perturbation of lymphoid maturation (by 324 
inhibition of EBF1 by EBF1-PDGFRB, or bypassing kinase induced senescence by 325 
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inactivation of ARF in the case of TNIP1ex14-PDGFRB) is required for lymphoid 326 
transformation, proliferation and self-renewal. 327 
  328 
EBF1-PDGFRB is leukemogenic, synergizes with IK6, and is antagonized by EBF1  329 
Because both IKZF1 alterations and CDKN2A (Arf) deletions are frequently observed in 330 
Ph-like cases harboring PDGFRB fusions, we co-modeled EBF1-PDGFRB with either 331 
empty vector or the dominant negative isoform of IKAROS (IK6) in primary Arf–/– pre-B 332 
cells to determine oncogenicity in vivo. In the absence of an oncogenic driver Arf–/– pre-333 
B cells, without or with IK6-expression, are not leukemogenic.33 We then transplanted 334 
1x106 Arf–/– pre-B cells expressing EBF1-PDGFRB together with empty vector or with 335 
IK6 by tail vein injection into sublethally irradiated WT recipients. EBF1-PDGFRB 336 
induced a fully penetrant leukemia with a median survival of 44 days (Figure 6a). 337 
Disease onset and spleen weight were significantly increased with co-expression of IK6, 338 
resulting in a median survival of 37 days (Figure 6a-b). Flow cytometric analysis of bone 339 
marrow and spleen from moribund mice revealed outgrowth of B-progenitor leukemia 340 
(CD43+ CD19+BP1+IgM–), with reduced B220 expression in the IK6-co-expressing pre-B 341 
cells compared with their EBF1-PDGFRB-only expressing counterparts (Figure 6c). 342 
Histological examination revealed that both EBF1-PDGFRB and EBF1-PDGFRB+IK6 343 
leukemias were highly infiltrative across multiple tissues including liver, lung and the 344 
central nervous system (Figure 6d). 345 
In leukemic patients, the high frequency of co-occurring lesions resulting in 346 
rearrangement or loss or EBF1 suggests that intact EBF1 may antagonize 347 
leukemogenesis. To test this, we infected Ebf1–/– cells with EBF1-PDGFRB alone, or 348 
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together with the 4-hydroxytamoxifen (4-OHT)-dependent EBF1:estrogen receptor 349 
fusion, which allows for intracellular EBF1 titration in vitro.24 We then sorted positive 350 
cells and expanded them in the absence of IL-7 across increasing dosages of 4-OHT 351 
(increasing EBF1 levels) while maintaining constant EBF1-PDGFRB levels 352 
(Supplementary Figures 11a-b). Increasing the dosage of active EBF1 significantly 353 
reduced the ability of EBF1-PDGFRB to confer IL-7 independence to Ebf1–/– progenitors 354 
in a dose-dependent manner. These results further support a model in which loss of 355 
EBF1 activity contributes to leukemogenesis. 356 
 357 
DISCUSSION 358 
In this study, we defined novel mechanisms of EBF1-PDGFRB-dependent 359 
leukemogenesis beyond dysregulated tyrosine kinase activity. Furthermore, we 360 
describe the first genetically faithful mouse model of Ph-like B-ALL, which confirms that 361 
EBF1-PDGFRB is sufficient to drive leukemogenesis in vivo. Additionally, EBF1-362 
PDGFRB synergizes with the dominant negative form of IKAROS, IK6. 363 
Mechanistically, we observed dual contributions of cytoplasmic mislocalization of 364 
EBF1-PDGFRB, which not only promotes constitutive TK signaling via STAT5 activation 365 
but also prevents EBF1 from localizing within nuclei, activating B cell specific genes, 366 
and promoting B lymphoid development (Figure 7). Surprisingly, removal of the TM 367 
domain resulted in nuclear relocalization of EBF1-PDGFRB and partial restoration of 368 
EBF1 function. Removal of the TM domain also restored IL-7 dependence to B cell 369 
progenitors expressing EBF1-PDGFRB, despite the presence of a functional TK domain. 370 
Interestingly, the EBF1 portion of EBF1-PDGFRB was not only required for IL-7 371 
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independence, but also appeared to protect the oncoprotein from TM-dependent 372 
cytoplasmic degradation as EBF1-PDGFRB was the only TM-containing construct that 373 
did not form cytoplasmic puncti (Supplementary Figure 12).  374 
We conclude that the PDGFRB TM domain facilitates both nuclear export and 375 
interactions with other cytosolic proteins, which in turn promote TK activity and 376 
transformation by EBF1-PDGFRB. Mislocalization by the TM/NES is likely a shared 377 
property of other PDGFRB-containing fusion proteins (e.g. ETV6-PDGFRB), which 378 
generally include this motif.34 Subcellular mislocalization and enhanced protein stability 379 
also contribute to leukemogenesis by other TK fusion proteins. For example, 380 
transforming activities of the NUP214-ABL1 fusion is dependent on its association with 381 
nuclear pore complexes.35 The mechanism that enhances stability of EBF1-PDGFRB is 382 
unknown, but it may be similar to the attenuation of proteosomal degradation reported 383 
for ETV6-PDGFRB, FIP1L1-PDGFRA, and ZMYM2(ZNF198)-FGFR1.36, 37 384 
The loss of EBF1 function in EBF1-PDGFRB is likely a key determinant of 385 
perturbed lymphoid maturation in B-ALL. This may, in part, account for the notably poor 386 
outcome of human EBF-PDGFRB+ B-ALL.38 Similar to the loss of IKZF1 due to deletion 387 
or dominant negative mutations, deletions of EBF1 genes or inhibition of EBF1 function 388 
in EBF1-PDGFRB impair B cell maturation and are associated with poor outcomes.39 In 389 
this regard, it is notable that restoration of EBF1 function in EBF1-PDGFRB, or enforced 390 
expression of EBF1, activated EBF1 target genes and blocked EBF1-PDGFRB-driven 391 
cell proliferation.  These observations indicate that re-establishment of EBF1 function in 392 
EBF1-PDGFRB+ B-ALL, i.e. using inhibitors of the TM/NES of PDGFRB,40 may provide 393 
an additional strategy for treating a subset of TKI-refractory leukemias. 394 
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Our studies highlight the importance of lineage maturation in preventing 395 
leukemogenesis. In B-ALL, the B cell-specific transcriptional network is perturbed, and 396 
genomic profiling studies have revealed that factors involved in B lymphoid specification, 397 
including IKZF1, PAX5 and EBF1 are commonly lost via mutation or deletion in >60% of 398 
patients, with a higher percentage in Ph+ and Ph-like cases.41-42 These alterations are 399 
associated with transcriptional dedifferentiation and poor outcomes.  Loss of normal 400 
EBF1 function is important for leukemogenesis by EBF1-PDGFRB, because intact 401 
EBF1 antagonizes functions of the fusion protein. We propose that EBF1-PDGFRB 402 
drives significant features of Ph-like B-ALL by itself, but is more potent in cells that have 403 
impaired homeostatic functions due to the loss of additional genes including the second 404 
allele of EBF1 itself, IKZF1, or by FLT3 gene duplications.3,39 Synergy between loss of 405 
these alterations and EBF1-PDGFRB has not been characterized at the molecular level; 406 
however, the loss of EBF1 and IKZF1 (e.g. IK6) together likely perturbs regulation of 407 
common genes and pathways.43 For example, alterations of IKZF1 results in arrested 408 
differentiation, acquisition of a hematopoietic stem cell-like phenotype, and confers 409 
resistance to TKI therapy in models of BCR-ABL1 positive ALL.44 Lesions in IKZF1 also 410 
activate expression of integrins and integrin signaling pathways.43,45 Together, effects of 411 
the loss of IKZF1 compound the loss of EBF1. In summary, our data confirm that loss of 412 
the tumor suppressor functions of EBF1, together with proliferative advantages provided 413 
by the TK function of PDGFRB, constitute a potent driver of leukemogenesis in B-ALL.  414 
 415 
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FIGURE LEGENDS 565 
 566 
Figure 1. EBF1-PDGFRB fails to activate EBF1 gene targets in B cell progenitors. (a) 567 
Schematic diagrams of WT EBF1, EBF1-PDGFRB, and WT PDGFRB proteins. 568 
Functional domains are listed along with relevant amino acid positions. Ig: 569 
Immunoglobulin-like (b) Quantitative RT-PCR analysis of endogenous gene activation 570 
by EBF1, EBF1-PDGFRB, or modified versions of these proteins in retrovirally 571 
transduced Ebf1–/– cells, without or with 1μM imatinib 72 hours post infection. All 572 
conditions were normalized to Hprt1 transcripts. MSCV-IRES-GFP (MIG) was used as a 573 
negative control. Error bars represent the mean ± SD of three independent replicates. 574 
****P<0.0001, ***P<0.0002, **P<0.002, *P<0.03. 575 
 576 
Figure 2. Mislocalization of EBF1-PDGFRB to the cytoplasm requires the TM domain of 577 
PDGFRB. (a-h) Confocal images of live, unfixed Ebf1–/– progenitors (100X 578 
magnification) expressing various constructs tagged with GFP (Supplementary Figures 579 
2 and 3b). Untethered mCFP was included in all experiments as an internal control to 580 
visualize whole cells. In overlays (column 4), Hoechst and GFP images are merged. (a) 581 
Untagged GFP and mCFP diffusely localizes to both nuclei and cytoplasm. (b-c) 582 
Nuclear vs. puncti localization patterns of EBF1-GFP compared with PDGFRB-GFP, 583 
respectively. (d) EBF1-PDGFRB-GFP localizes diffusely throughout the cytoplasm, 584 
which is not affected by kinase inactivation (e), but is highly dependent upon the 585 
presence of the intact TM domain (f-g). (h) EBF1-TM localizes in cytoplasmic puncti.  586 
 587 
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Figure 3. EBF1-PDGFRB multimerizes, is phosphorylated on tyrosine residues, and is 588 
stabilized in Ebf1–/– progenitors. (a) Co-IP demonstrating multimerization of Myc- and 589 
FLAG-tagged EBF1-PDGFRB in Ebf1–/– cells. (b) EBF1-PDGFRB and EBF1 localize to 590 
non-overlapping compartments in live cells. Confocal microscopy detecting co-591 
expression of EBF1-PDGFRB-GFP and EBF1-mCFP in Ebf1–/– B progenitor cells. 592 
EBF1-PDGFRB is restricted to cytoplasm, while EBF1 is detected only in nuclei of the 593 
same cells (c) IP followed by immunoblots demonstrate that EBF1-PDGFRB is 594 
autophosphorylated. Phosphorylation is blocked by imatinib and the K634R mutation. 595 
(d) Stability of EBF1-PDGFRB fusion, PDGFRB, and  PDGFRB(528-1106) in the 596 
presence of cycloheximide. Antibodies used for IP and blotting are indicated.  597 
 598 
Figure 4. EBF1-PDGFRB and other PDGFRB fusions promote cytokine-independent 599 
and clonogenic growth of B cell progenitors through STAT5, ERK and AKT 600 
phosphorylation. EBF1-PDGFRB-mediated transformation requires a TM domain. (a) 601 
Growth curve of Ebf1–/– cells infected (in triplicate) to express proteins as shown. GFP+ 602 
cells were sorted and grown over 16 days in the absence of IL-7, and counted every 48 603 
hours. 1μM imatinib was added at day 9 to all cultures. Asterisks represent P<0.0001 604 
for EBF1-PDGFRB compared with negative control. (b) Ba/F3 and Arf−/− pre-B cells 605 
were transduced with TNIP1ex14-PDGFRB, TNIP1ex17-PDGFRB, ATF7IP-PDGFRB, 606 
CD74-PDGFRB, or EBF1-PDGFRB and grown in the absence of IL-3 or IL-7, 607 
respectively, and counted every two days. (c) Phosflow analysis of pSTAT5, pAKT, and 608 
pERK in transduced Ba/F3 cells with or without 100nM dasatinib treatment for one hour. 609 
(d) Cytotoxicity assays of Ba/F3 cells transduced to express fusion proteins as in (b), 610 
Running head: EBF1-PDGFRB IN B-CELL LEUKEMOGENESIS  
 
 29
followed by incubation with dasatinib, crenolanib, or dovitinib. Cultures were sampled at 611 
Error bars represent means ± SD.  612 
 613 
Figure 5. Re-plating activity of progenitors expressing PDGFRB fusions. (a) EBF1-614 
PDGFRB or TNIP1ex14-PDGFRB transduction of lineage-negative WT or Arf–/– cells in 615 
semi-solid methylcellulose containing IL7, FLT3L, and SCF resulted in sustained re-616 
plating of B lymphoid colonies. All cells collected from rounds three to six of re-plating 617 
were analyzed for (b) cell morphology and (c) flow cytometric detection of Lineage 618 
Panel vs. Hardy Panel staining. Data in (c) is representative of Arf–/–-, EBF1-PDGFRB-619 
positive cells collected from methylcellulose after three rounds of re-plating. Error bars 620 
represent the mean ± SD of three biological replicates. 621 
 622 
Figure 6. EBF1-PDGFRB is leukemogenic, cooperates with IK6, and produces a fully 623 
penetrant disease. (a) Transplantation of in vitro-derived EBF1-PDGRFB transformed 624 
Arf–/– pre-B cells with co-transduction of empty vector or IKAROS dominant negative IK6, 625 
which lacks the N-terminal DNA-binding zinc fingers due to deletion of exons 4-7. 626 
Statistical significance was assessed by log rank Mantel-Cox (P < 0.0005) and n = 15 627 
mice per group (5 mice each from three independent pre-B cell transductions). (b) Mice 628 
inoculated with pre-B cells co-expressing EBF1-PDGFRB and IK6 had increased 629 
splenic infiltration, as determined by spleen weight. The data points ± SD are plotted, 630 
P < 0.0005. (c) Representative flow cytometric analysis of bone marrow from 631 
moribund mice detecting hematopoietic lineage markers CD43, B220, CD19, BP1, and 632 
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IgM. (d) Representative histology from EBF1-PDGFRB or EBF1-PDGFRB + IK6 633 
leukemia infiltrated tissues.  634 
 635 
Figure 7. Proposed model of EBF1-PDGFRB (E-P) leukemogenesis. (a) Leukemic cells 636 
harbor the EBF1-PDGFRB (E-P) fusion protein, which homodimerizes, 637 
autophosphorylates, and activates STAT5 signaling promoting aberrant proliferation. 638 
Leukemia cells fail to differentiate due to sequestration of EBF1 (in the form of E-P) 639 
outside of nuclei. E-P can synergize with IKAROS loss-of-function, which is imposed by 640 
the dominant-negative isoform IK6. (b) Treatment with imatinib blocks E-P TK activity 641 
and downstream STAT5 signaling, but fails to restore differentiation. (c) Deletion of the 642 
TM motif results in relocalization of E-P proteins into nuclei, resulting in partial 643 
restoration of the B cell program. 644 
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